Gene therapy for HIV infection by 'intracellular immunization' with antiviral genes

AIDS Reviews

Volumn 3, Issue 3, 2001, Pages 169-177

  Von Laer, D ^a   Brandenburg, G ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Antiviral genes; Gene therapy; HIV dynamics

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; CHEMOKINE RECEPTOR CCR5; COMPLEMENTARY RNA; CYTOKINE; ENZYME ANTIBODY; GAG PROTEIN; GENE PRODUCT; INTEGRASE; INTERLEUKIN 16; M 87; MEMBRANE PROTEIN; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; PRIMER BINDING SITE DECOY; PROTEIN ANTIBODY; RECEPTOR ANTIBODY; REV PROTEIN; RIBOZYME; RNA DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RRE DECOY; SOLUBLE CD4 ANTIGEN; TAR DECOY; TRANSACTIVATOR PROTEIN; TRANSFER RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS FUSION PROTEIN; VIRUS PROTEIN; VIRUS RNA; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CELL PROTECTION; CELL SURVIVAL; CELL TYPE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOPATHOGENIC EFFECT; DNA MODIFICATION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG EFFECT; DYNAMICS; GENE EXPRESSION; GENE FUNCTION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INHIBITION KINETICS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TARGET CELL; VIRION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

EID: 0035195551     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Gene therapy clinical trials
2. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture
3. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy
4. Clinical trial of stem cell gene therapy in HIV 1-infected children
5. Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor elF-5A
6. Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): Delivery by SV40 provides durable protection against HIV-1 and does not require selection
7. Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy
8. Development of lentiviral vectors for gene therapy for human diseases
9. Approaches to gene therapy for human immunodeficiency virus infection
10. Efficient in vivo marking of primary CD4+ T lymphocytes in nonhuman primates using a gibbon ape leukemia virus-derived retroviral vector
11. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes
12. Antisense RNA sequences targeting the 5′ leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle
13. Retrovirally mediated IFN-beta transduction of macrophages induces resistance to HIV, correlated with up-regulation of RANTES production and down-regulation of C-C chemokine receptor-5 expression
14. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics
15. Co-packaging of sense and antisense RNAs: A novel strategy for blocking HIV-1 replication
16. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody
17. Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket
18. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5
19. Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins
20. A phase I clinical trial to evaluate the safety and biological activity of HIV-IT (TAF) (HIV-1IIIBenv-transduced, autologous fibroblasts) in asymptomatic HIV-1 infected subjects
21. Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades
22. Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals
23. An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects
24. Membrane-anchored peptide inhibits human immunodeficiency virus entry
25. Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single-chain variable fragments
26. Human Kupffer cells infected with HIV-1 in vivo
27. Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression
28. Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication
29. Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase
30. Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro
31. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children
32. Exploring interferon beta for gene therapy of HIV infection
33. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain
34. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells
35. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase
36. Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: Preclinical studies
37. Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer
38. Inhibition of HIV-1 replication using a mutated tRNALys-3 primer
39. Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant repressor of Rev function
40. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication
41. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant
42. Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA
43. Gene-transferred oligoclonal T cells predominantly persist in peripheral blood from an adenosine deaminase-deficient patient during gene therapy
44. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects
45. Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: Demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1
46. Retroviral vectors expressing soluble CD4: A potential gene therapy for AIDS
47. Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: Long-term expression in vivo of genes introduced with a retroviral vector
48. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat
49. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
50. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: Implication for gene therapy of AIDS
51. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments
52. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat
53. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals
54. Retroviral vector-mediated expression in primary human T cells of an endoplasmic reticulum-retained CD4 chimera inhibits human immunodeficiency virus type-1 replication
55. Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice
56. Experimental gene therapy: The transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice
57. Ribozymes as potential anti-HIV-1 therapeutic agents
58. Antiretroviral effect of a gag-RNase HI fusion gene
59. Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo
60. Inhibition of human immunodeficiency type 1 replication in human cells stably expressing antisense RNA
61. Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle
62. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion
63. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication
64. Preferential survival of syngeneic CD4+ lymphocytes transduced with anti-sense TAR and transdominant Rev protein genes
65. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus
66. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes
67. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein
68. CD34+ hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus
69. Low percentage of blood and bone marrow monocytes infected with the human immunodeficiency virus (HIV-1) in vivo
70. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults
71. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme
72. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients
73. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells
74. Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1
75. Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition of mRNA expression